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Translational Relevance 49
Urinary bladder urothelial carcinoma (UBUC) is a common malignant disease, especially 50 in developed countries. Almost 50% of patients eventually progress and develop systemic 51 disease. Cell cycle dysregulation resulting in uncontrolled cell proliferation has been 52 associated with UBUC development. Thus, restoring the function of a critical molecule is a 53 rational approach for UBUC treatment. In this study, we performed data mining and 54 identified a potential tumor suppressor, TMCO1, in UBUCs. Clinical associations, xenograft 55 mice and in vitro indications from distinct UBUC-derived cell lines provided strong evidence 56 that the TMCO1 gene is a novel tumor suppressor via the inhibition of the AKT signaling 57 pathway. Downregulation of the TMCO1 protein can be used as an adverse prognostic factor 58 for inferior outcomes in UBUC patients. Our findings provide important insights into the 59 mechanisms of UBUC development and highlight the potential targets for therapeutic 60 interventions. complicates the use of general therapies (6). Cell cycle dysregulation resulting in 92 uncontrolled cell proliferation has been associated with UBUC development (7,8). Thus, 93
targeting a critical molecule for therapies is a rational approach for UBUC treatment (9). 94
To identify transcripts that are potentially involved in UBUC development, data mining 95 established expression profiles (GSE31684, n = 93) in the Gene Expression Omnibus 96 database (GEO, NCBI, Bethesda, MD, USA) was performed. One differentially expressed 97 transcript, transmembrane and coiled-coil domain 1 (TMCO1), was identified to be associated 98 with growth factor activity (GO:0008083; molecular function) and was highly expressed in 99 pTa (P = 0.0006) and pT1 (P = 0.0174), compared to pT2-T4 patients with UBUC. The 100 human TMCO1 gene, mapped to human chromosome 1q24.1, encodes a transmembrane 101 protein (10), is a member of the DUF841 superfamily of several eukaryotic proteins with 102 unknown function or involvement in any biological process (11). The 3D structure of 103 TMCO1 protein has not be resolved, yet its topology contains 2 transmembrane domains 104 (#10-30; #91-111) and 1 intramembrane fragment (#138-154) (12). Green fluorescent 105
protein-tagged and Myc-tagged TMCO1 were found to be expressed in the endoplasmic 106 reticulum (ER) and/or the Golgi apparatus of COS7 and HeLa cells (12, 13) . TMCO1 mRNA 107 is highly expressed in porcine heart, liver and kidney (14) . Data mining, and the fact that 
calculation (21). 159
Immunoblot analyses were performed as in our previous study (Supplementary Materials and 160
Methods). 161 162
Expression plasmids, stable and transient transfections 163
The pCMV6-TMCO1 (RC200219; NM_019026.4) plasmid was purchased from OriGene 164
Technologies. The TMCO1 complete DNA (564 bp) was subcloned into a pHTC HaloTag 165 CMV-neo vector (pHaloTag) using 5'-CTAGCTAGCATGAGCACTATGTTCGCGGA-3' and 166
5'-CCGCTCGAGAGAGAACTTCCCAGAAGGAGGT-3' primers with Nhe I and Xho I 167 restriction sites (underlined) to generate the pTMCO1-HaloTag plasmid. The 168 pcDNA3-PHLPP2 (#22403) and pHRIG-AKT1 (#53583) plasmids were obtained from 169 Addgene (22,23). All plasmids were sequence verified. Cells (5  10 5 ) were transfected with 170 2.5 g of a specific plasmid by mixing with 7.5 L of PolyJet reagent (SignaGen 171 Laboratories) in Opti-MEM (Life Technology). Transfectants were selected with medium 172 containing 800 g/mL of G418 (AMRESCO) for 7 days and maintained in medium with 400 173 g/mL of G418 for subsequent experiments. The same protocol was used for transient 
Immunocytochemistry and co-immunoprecipitation 200
To examine whether TMCO1 colocalizes or interacts with PHLPP1 or PHLPP2, 201 immunocytochemistry and co-immunoprecipitation (co-IP) were performed using our 202 previous procedures (24), and details are described in Supplementary Materials and Methods. 203 204
Site-directed mutagenesis 205
Three plasmids, pTMCO1(T33A)-, pTMCO1(S60A)-and pTMCO1(S84A)-HaloTag with 206 mutations at residues #33, #60 or #84 from threonine/serine to alanine of the TMCO1 protein 207 were constructed using the QuikChange Lightning Site-Directed Mutagenesis Kit (#210518, 208
Cancer Research. All calculations were performed using SPSS 14.0 software. To determine the prognostic 238 impact of selected transcripts identified in GSE31684, the deposited cases were subdivided 239 into two clusters based on the expression level of each transcript, detected by a specific probe 240 and computerized by k-means clustering (k = 2). The survival difference of the two clusters 241 was next calculated by log-rank analysis and plotted using the Kaplan-Meier method for 242 overall survival. The association and comparison between various clinicopathological factors 243 and TMCO1 expression were assessed by the Chi-square test. The endpoint analyzed for 244 survival analysis was disease-specific and metastasis-free survivals. Student's t-test was used 245 to examine the significance of differences in fold changes of mRNA levels, cells in different 246 phases of the cell cycle, percentages of cell viability, proliferation and anchorage-independent 247 cell growth. Comparison of xenograft tumor sizes was performed by using one-way ANOVA. 248
For other analyses, two-sided tests of significance were used, and a P value of < 0.05 was 249 considered to be statistically significant. 250
251
Results
252
Data mining identifies that the TMCO1 transcript is downregulated in the progression 253 of UBUCs, and TMCO1 downregulation confers poor outcomes in UBUC patients 254
From the transcriptomic profiles of 308 UBUCs deposited in the GEO database using 255
Illumina HumanHT-12 V3.0 Expression BeadChip for analysis, GSE32894, the TMCO1 256 transcript was found to be significantly downregulated in muscle-invasive compared to 257 non-muscle-invasive UBUCs (Fig. 1A) mRNA level was highly expressed in non-tumor (P = 0.001) and low-stage (pTa-T1; P = 262 0.004), compared to high-stage (pT2-T4) UBUC patients. High TMCO1 expression was also 263 identified in non-tumor urothelium and non-invasive urothelial carcinomas compared to 264 muscle-invasive carcinomas (Fig. 1D) . Correlations between TMCO1 expression and various 265 clinicopathological factors are listed in Supplementary Table S2 . Univariate log-rank analysis 266 identified that pT, nodal metastasis, histological grade, vascular invasion, perineural invasion, 267 mitotic rate and TMCO1 immunostainings were significantly correlated with disease-specific 268 and metastasis-free survivals in 295 UBUC patients (Table 1) . Kaplan-Meier plots revealed 269 that low TMCO1 protein levels predicted poor disease-specific survival (P = 0.0001; Fig. 1E ) 270 and metastasis-free survival (P < 0.0001; Fig. 1F ). Multivariate analysis additionally 271 demonstrated that pT, mitotic rate and TMCO1 protein level significantly correlated to 272 disease-specific survival; pT, nodal metastasis and TMCO1 protein level considerably 273 correlated with metastasis-free survival (Table 1) . These results suggest that low TMCO1 274 protein level confers an independent prognostic indicator in UBUC patients. Array 275 comparison genomic hybridization (aCGH) was performed, as analyzed (40 UBUCs) in our 276 previous study (25), and showed frequent DNA copy number gain at loci spanning TMCO1 277 gene at 1q24.1 (9/40, 22.5%), excluding the possibility of TMCO1 gene deletion in UBUC 278 patients ( Supplementary Fig. S1 ). Thus, downregulation of TMCO1 protein is an independent 279 prognostic factor in UBUCs. The TMCO1 mRNA levels were highly expressed in HUC, RT4 and J82 cells and low in 284 BFTC905 cells ( Fig. 2A) . Additionally, TMCO1 protein levels were high in RT4 and J82 285 cells and low in BFTC905 ( protein levels, induced cell cycle progression to S phase (P < 0.001), and increased cell 297 viability (P < 0.01), cell proliferation (P < 0.01) and colony 298 formation/anchorage-independent cell growth (P < 0.001) ( Fig. 2I-2N ). These findings 299 suggest that TMCO1 functions as a tumor suppressor by regulating cell cycle progression in 300
vitro. 301
Stable exogenous expression of the TMCO1 gene in BFTC905 cells notably upregulated 302 the protein levels of the TMCO1-HaloTag, RB transcriptional corepressor 1 (RB1), TP53, 303 pTP53(S15), cyclin dependent kinase inhibitor 1A (CDKN1A) and CDKN1B; however, 304 TMCO1 stable expression also downregulated cyclin D1 (CCND1), cyclin dependent kinase 305 4 (CDK4), CCNE1, and CDK2 protein levels ( pCDKN1A(T145)/CDKN1A or pCDKN1B(T157)/CDKN1B ratio indicates an increase in the 309 corresponding active form. Upregulation of nuclear TP53 and CDKN1A, rather than the 310 cytosolic forms, accounted for the total TP53 and CDKN1A levels (Fig. 2P ). However, TP53 311 mRNA levels remained unchanged (NS; Supplementary Fig. S2B ), suggesting that TMCO1 312 might stabilize TP53 at the protein level. Accordingly, the expression levels of MDM2, an E3 313 ubiquitin ligase of TP53, and its upstream regulators, AKT and pAKT1(S473) (26), were next 314 examined. Substantial downregulation of pAKT1(S473), MDM2 and pMDM2(S166) proteins 315
were found in TMCO1-overexpressed BFTC905 (Fig. 2Q) . 316
Stable TMCO1-knockdown RT4 cells exhibited an opposite protein expression pattern 317 compared to TMCO1-overexpressed BFTC905 cells (Fig. 2R) . The ratios of 318 pCDKN1A(T145) (inactive)/CDKN1A (shTMCO1#3: 0.70; shTMCO1#5: 0.89) and 319 pCDKN1B(T157) (inactive)/CDKN1B (shTMCO1#3: 0.92; shTMCO1#5:0.92) were similar 320 to the control (shLuc) (Fig. S2C) . Nuclear TP53 and CDKN1A as well as nuclear and 321 cytosolic CDKN1B were downregulated (Fig. 2S ), yet TP53 mRNA levels were upregulated 322 (P < 0.05; Supplementary Fig. S2D ). Further, treatment with a proteasome inhibitor, MG132, 323 increased the abundance of the TP53 protein in the shLuc group compared to the DMSO 324 control. MG132 further restored shTMCO1-suppressed TP53 protein levels in RT4 cells (Fig.  325 2T), reinforcing the observation that TMCO1 stabilizes TP53 at the protein level. Stable 326 knockdown of the TMCO1 gene in J82 cells showed similar results to TMCO1-knockdown 327 RT4 cells, except the levels of phospho/inactive CDKN1A (shTMCO1#3: 1.89; shTMCO1#5: 328 2.42) and CDKN1B (shTMCO1#3: 1.76; shTMCO1#5: 1.67) were much higher than the 329 shLuc control, implying that TMCO1 predominantly inhibits phospho/inactive CDKN1A and 330 CDKN1B in J82 cells (Fig. S3A-S3G Fig. S4 ). 334
To evaluate whether TMCO1-suppressed cell proliferation was AKT signaling-dependent, 335 a constitutively active AKT1 plasmid, pHRIG-AKT1 (23), was co-transfected with the 336 pTMCO1-HaloTag plasmid into BFTC905 cells. Exogenous constitutive expression of the 337 active AKT1 gene markedly downregulated TMCO1-induced levels of RB1, TP53, 338 pTP53(S15), CDKN1A, and CDKN1B, while it upregulated the TMCO1-suppressed protein 339 levels of pCDKN1A(T145), pCDKN1B(T157), CCND1, CDK4, CCNE1, CDK2, exogenous 340 AKT1 and pAKT1(S473), MDM2, and pMDM2(S166) (Fig. 2U) as well as phospho/inactive 341 CDKN1A and CDKN1B ( PHLPPs dephosphorylate the S473 residue (22) and protein phosphatase 2 catalytic subunit 360 alpha (PPP2CA) dephosphorylates the T308 residue (27) of AKT1. Since the TMCO1 protein 361 contributes to the deactivation of AKT1, we first hypothesized that TMCO1 might regulate 362 PHLPP1 or PHLPP2 protein expression. However, PHLPP1 or PHLPP2 protein level was not 363 altered after TMCO1 overexpression in BFTC905, RT4 or J82 cells (Fig. 4A) . A dose-course 364 experiment was conducted in BFTC905 cells and 15 M was found to be effective for a 365 pan-PHLPP inhibitor, NSC117079 (Supplementary Fig. S6 ). In TMCO1-overexpressed 366 BFTC905 cells, treatments with NSC117079 upregulated pAKT1(S473) compared to 367 DMSO/pHaloTag (control) and DMSO/pTMCO1-HaloTag transfectants. Moreover, 368 compared to NSC117079/pHaloTag, pAKT1(S473) was downregulated in 369 NSC117079/pTMCO1-HaloTag transfectants (Fig. 4B) . Hence, PHLPPs are indeed involved 370 in TMCO1-mediated dephosphorylation of pAKT1(S473). Confocal immunocytochemistry 371 insinuated that TMCO1 were predominately colocalized with PHLPP2 protein (Fig. 4C) , 372 while only somewhat colocalized with PHLPP1 ( Supplementary Fig. S7 ) in BTFC905 and 373 RT4 cells. Co-IPs additionally demonstrated that PHLPP2, rather than PHLPP1, interacted 374 with TMCO1 in RT4 and J82 cells (Fig. 4D) . These results suggested that TMCO1 recruits 375 PHLPP2 to dephosphorylate pAKT1(S473) in UBUC-derived cells. Exogenous expression of 376 both TMCO1 and PHLPP2 remarkably downregulated pAKT1(S473) protein level (Fig. 4E ) 377 and AKT activity (Fig. 4F ) in BFTC905 cells compared to overexpression of either TMCO1 378 or PHLPP2 alone, indicating that TMCO1 recruits PHLPP2 to deactivate pAKT1(S473). reside in the cytoplasmic region (Fig. 5A) . We therefore, constructed 3 plasmids containing 384 TMCO1 with T33A, S60A and S84A mutations to evaluate whether these potential 385 phosphorylation sites are critical for TMCO1 function. As shown in Fig. 5B, overexpression  386 of the TMCO1(WT) or each mutant in BFTC905 cells notably upregulated TMCO1(WT)-, 387 TMCO1(T33A)-, TMCO1(S60A)-, TMCO1(S84A)-HaloTag, pAKT1(S473), MDM2, 388 pMDM2(S166), and downregulated TP53, pTP53(S15), and CDKN1A protein levels. 389
Overexpression of TMCO1(S60A), but not other mutants, released TMCO1(WT)-induced G 1 390 cell cycle arrest (Fig. 5C ), , and increased AKT1 activity (Fig. 5D ) compared to TMCO1(WT) 391 overexpression. Neither WT nor any other mutant affected the TP53 mRNA level (NS; Fig.  392 S2E). Accordingly, S60 in the TMCO1 protein was found to be critical for the expression and 393 stability of pAKT1(S473), MDM2, pMDM2(S166), TP53, pTP53(S15), and CDKN1A 394 proteins, and AKT activity. 395
Mouse xenograft models were further applied to evaluate the effect of TMCO1 in vivo. In 396 NOD/SCID mice, xenografts of BFTC905 cells with TMCO1(WT) (P = 0.007) and 397 TMCO1(S84A) (P = 0.039) overexpression showed smaller tumors compared to the control 398 (HaloTag) after mice were sacrificed. When compared to the TMCO1(WT) group, the 399 TMCO1(T33A) (P = 0.036) and TMCO1(S60A) (P = 0.006) groups exhibited larger tumors. 400
The TMCO1(S60A) group possessed greater tumor mass than TMCO1(S84A) (P = 0.035) 401 ( Fig. 5E; Supplementary Fig. S8 ). Stable TMCO1(WT) overexpression induced a large area 402 of necrosis and a much lower percentage of cancer components. Ki-67 was highly expressed 403 in pTMCO1(T33A)-and pTMCO1(S60A)-HaloTag-expressing xenografts compared to 404 pHaloTag xenografts (Fig. 5F ), suggesting that TMCO1(S60A) and TMCO1(T33A) mutants 405 particularly impair the growth inhibitory property of the TMCO1 protein in vivo. In HTB-33 406 epithelial cells (cervix, derived from metastatic site, omentum), TMCO1 functions as a tumor 407 suppressor in vitro and in vivo ( Supplementary Fig. S9 ), thus reinforcing our findings. 
Discussion 410
In this study, we found that a high TMCO1 protein level could be an independent 411 prognostic factor for disease-specific and metastasis-free survivals in a subset of UBUC 412 patients. In addition, low TMCO1 protein levels correlated with aggressive tumor behaviors. 413
We further identified that some patients (most were non-muscle invasive UBUCs, data not 414 shown) with low TMCO1 protein levels showed long-term survival. Recent genomic and 415 transcriptomic experiments indicated that non-muscle invasive UBUCs and carcinoma in situ 416 in 4 distinct UBUC-derived cell lines and UBUCs with low TMCO1 protein levels. Thus, the 434 possibility that methylation in the promoter region caused low TMCO1 transcription was 435 excluded. In addition, no evidence of the TMCO1 gene deletion was found from our previous 436 aCGH data (25) . Accordingly, the regulation of TMCO1 mRNA and subsequent protein levels 437 might be attributed to the activities of its transcriptional factors or other epigenetic 438 modifications except methylation. 439
We further identified that TMCO1 inhibits cell cycle progression accompanied with 440 alterations of pAKT1(S473), MDM2, pMDM2(S166), TP53, pTP53(S15) and nuclear TP53, and PHLPP2 genes synergistically decreased pAKT1(S473) level and AKT1 activity 468 compared to overexpression of either the TMCO1 or PHLPP2 gene alone. Together, these 469 data support the concept that TMCO1 recruits PHLPP2 to dephosphorylate pAKT1(S473). In 470 a well-characterized mechanism, AKT downregulates TP53 protein level by enhancing 471
MDM2-mediated targeting of TP53 degradation (35). Under nonstress conditions, MDM2, an 472
E3 ligase of TP53, binds to TP53 and monoubiquitinates it prior to exporting TP53 to the 473 cytoplasm, where it is polyubiquitinated. AKT-dependent phosphorylation of MDM2 on S166 474 facilitates this export (36). Therefore, TMCO1-suppressed pMDM2(S166) radically 475 facilitated the stability of the TP53 protein. Moreover, phosphorylation on S15 of the TP53 476 protein, i.e., pTP53(S15), is necessary to mediate TP53-dependent transcription (especially 477 CDKN1A) and growth arrest (37). In parallel to this scenario, a novel tumor suppressor, 478 TMCO1 is uncovered and found to recruit PHLPP2 to dephosphorylate pAKT1(S473), 479 downregulate MDM2 and phospho/active pMDM2(S166), upregulate TP53 and 480 phospho/active/nuclear pTP53(S15) and inhibit cell proliferation. 481
In addition to TP53, we also found that TMCO1 upregulates nuclear CDKN1A, and 482 downregulates phospho/inactive CDKN1A and CDKN1B in BFTC905 and J82, but not RT4 TMCO1-suppressed cell proliferation might be partially CDKN1A-and/or 498 CDKN1B-dependent, since TMCO1 positively regulated nuclear/active CDKN1A and 499 CDKN1B protein levels in vitro. Knockdown of the TMCO1 gene was not able to upregulate 500 phospho/inactive CDKN1A and CDKN1B, implying that AKT1 might not be the only kinase 501 to phosphorylate CDKN1A and CDKN1B. Although CDKN1A can be induced by both 502 TP53-dependent and -independent mechanisms, our findings are compatible with either 503
pathway. 504
Among three mutants disrupting potential phosphorylation sites in the cytoplasmic region, 505
we revealed that overexpression of the TMCO1(S60A), but not TMCO1(T33A) or 506 TMCO1(S84A), protein reverses TMCO1-mediated AKT activity to 85%; pAKT1(S473), 507 pMDM2(S166), pTP53(S15), CDKN1A protein levels, and cell cycle arrest, suggesting that 508
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knockdown of the TMCO1 gene was also reported, thus strengthening the tumor suppressor 534 roles of TMCO1 in cell migration in vitro. 535
Overall, we demonstrate low TMCO1 protein levels in a subset of UBUCs with aggressive 536 behaviors. In distinct UBUC-derived cell lines, TMCO1 expression inhibited cell 537 proliferation by modulating the protein levels of pAKT1(S473), MDM2, pMDM2(S166), 538 TP53, pTP53(S15), nuclear/active CDKN1A and CDKN1B, CD44 and VIM in combination 539 with decreasing cell viability, proliferation, colony formation/anchorage-independent cell 540 growth, cell migration and invasion. Additionally, TMCO1 was found to recruit PHLPP2 to 541 dephosphorylate pAKT1(S473) and reduce AKT activity, and the intramembrane S60 residue 542 of the TMCO1 protein was found to play a crucial role in this AKT-dependent pathway. into BFTC905 cells notably downregulated RB1, TP53, pTP53(S15), CDKN1A and 594 CDKN1B and upregulated pCDKN1A(T145), pCDKN1B(T157), CCND1, CDK4, CCNE1, 595 CDK2, exogenous pAKT1(S473), MDM2, and pMDM2(S166) protein levels compared to 596 the pTMCO1-HaloTag group. (V) BrdU assay further showed that constitutively active AKT1 597 increased cell proliferation compared to the control (transfection of pHaloTag) and the 598 pTMCO1-HaloTag-transfected groups. All experiments were conducted in triplicate, and 599 results are expressed as the mean SEM. For immunoblot analysis, one representative image 600 is shown; GAPDH served as a loading control; GAPDH and PARP1 were used as cytosolic 601 and nuclear control, respectively. Statistical significance: *, P < 0.05; **, P < 0.01; ***, P < 602 0.001. 
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